Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2015

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA07 - Overcoming Resistance to EGFR Inhibitors

    • 12:15 - 13:15
    • 8/08/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Mini Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      Session Moderator

      13:07 - 13:15  |  Presenter: Dana Lucia Stanculeanu

      • Abstract

      Loading...

    • +

      Session Moderator

      13:07 - 13:15  |  Presenter: Ross Soo

      • Abstract

      Loading...

    • +

      MA07.01 - Session Introduction

      12:15 - 12:16  |  Presenter: Dana Lucia Stanculeanu

      • Abstract

      Loading...

    • +

      MA07.02 - Session Introduction

      12:16 - 12:17  |  Presenter: Ross Soo

      • Abstract

      Loading...

    • +

      MA07.03 - Real-world Landscape of EGFR C797X Mutation as a Resistance Mechanism to Osimertinib in Non-small Cell Lung Cancer

      12:17 - 12:22  |  Presenter: Suresh S. Ramalingam

      • Abstract

      Loading...

    • +

      MA07.04 - Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC

      12:22 - 12:27  |  Presenter: Melina Elpi Marmarelis

      • Abstract

      Loading...

    • +

      MA07.05 - Phase 1b/2 Study of Combined HER Inhibition in Refractory EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

      12:27 - 12:32  |  Presenter: Jonathan Goldman

      • Abstract

      Loading...

    • +

      MA07.06 - Discussant

      12:32 - 12:42  |  Presenter: Laura Mezquita

      • Abstract

      Loading...

    • +

      MA07.07 - Clinical/Molecular Profile of Patients with Non-small Cell Lung Cancer (NSCLC) with Incidental Pathogenic Germline Variants Detected in cfDNA

      12:42 - 12:47  |  Presenter: Laura Mezquita

      • Abstract

      Loading...

    • +

      MA07.08 - JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC

      12:47 - 12:52  |  Presenter: Byoung Chul Cho

      • Abstract

      Loading...

    • +

      MA07.09 - BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study

      12:52 - 12:57  |  Presenter: Sun Min Lim

      • Abstract

      Loading...

    • +

      MA07.10 - Discussant

      12:57 - 13:07  |  Presenter: Pasi A Janne

      • Abstract

      Loading...

    • +

      MA07.11 - Live Q&A

      13:07 - 13:15

      • Abstract

      Loading...